Recent advances in neonatal pharmacotherapy

Annals of Pharmacotherapy

Volumn 40, Issue 4, 2006, Pages 710-719

  Calhoun, Darlene A ^a   Murthy, S Narasimha ^b   Bryant, Bobby G ^b   Luedtke, Sherry A ^c   Bhatt Mehta, Varsha ^d,e  

^a SARASOTA MEMORIAL HOSPITAL   (United States)

^b OHIO NORTHERN UNIVERSITY   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Neonates; Patent ductus arteriosus; Persistent pulmonary hypertension

Indexed keywords

ADENOSINE; ALCOHOL; CYCLIC GMP; DIPYRIDAMOLE; ERYTHROPOIETIN; HEMOPOIETIC GROWTH FACTOR; IBUPROFEN; INDOMETACIN; LIDOCAINE; LOCAL ANESTHETIC AGENT; NITRIC OXIDE; PENETRATION ENHANCING AGENT; PHOSPHODIESTERASE INHIBITOR; PRILOCAINE; PROPYLENE GLYCOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SILDENAFIL; TETRACAINE; VASODILATOR AGENT;

AMNION FLUID; BURN; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; IONTOPHORESIS; KIDNEY DYSFUNCTION; NECROTIZING ENTEROCOLITIS; NEUROPROTECTION; NEWBORN; NEWBORN DISEASE; OLIGURIA; PATENT DUCTUS ARTERIOSUS; PERINATAL ASPHYXIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SKIN NECROSIS;

ANIMALS; DRUG THERAPY; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 33646250930     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G212     Document Type: Review

References (96)

1. Roberts RL, Szelc CM, Scates SM, et al. Neutropenia in an extremely premature infant treated with recombinant human granulocyte colony-stimulating factor. Am J Dis Child 1991;145:808-12.
2. Lejkowski M, Maheshwari A, Calhoun DA, Christensen RD, Skoda-Smith S, Dabrow S. Persistent perianal abscess in early infancy as a presentation of autoimmune neutropenia. J Perinatol 2003;23:428-30.
3. Maheshwari A, Christensen RD, Calhoun DA. Immune-mediated neutropenia in the neonate. Acts Paediatr Suppl 2002;91:98-103.
4. Ohls RK. The use of erythropoietin in neonates. Clin Perinatol 2000;27:681-96.
5. Ohls RK, Wirkus PE, Christensen RD. Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease. Pediatrics 1992;90:678-80.
6. Dvorak B, Stephana AL, Holubec H, Williams CS, Philipps AF, Koldovskoy O. Insulin-like growth factor-I (IGF-I) mRNA in the small intestine of suckling and adult rats. FEBS Lett 1996;388:155-60.
7. Dvorak B, Fituch CC, Williams CS, Hurst NM, Schanler RJ. Increased epidermal growth factor levels in human milk of mothers with extremely premature infants. Pediatr Res 2003;54:15-9.
8. Koldovsky O. The potential physiological significance of milk-borne hormonally active substances for the neonate. J Mammary Gland Biol Neoplasia 1996;1:317-23.
9. Maheshwari A, Lu W, Lacson A, et al. Effects of interleukin-8 on the developing human intestine. Cytokine 2002;20:256-67.
10. Gersting JA, Du Y, Christensen RD, Calhoun DA. Effects of enterally administering granulocyte colony-stimulating factor to suckling mice. Pediatr Res 2004;55:802-6.
11. Gersting JA, Kotto-Kome AC, Du Y, Christensen RD, Calhoun DA. Bioavailability of granulocyte colony-stimulating factor administered enterally to suckling mice. Pharmacol Res 2003;48:643-7. PMID 12660437
12. Juul SE, Ledbetter DJ, Joyce AE, et al. Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 2001;49:182-9.
13. Calhoun DA, Juul SE, McBryde EV, Veerman MW, Christensen RD. Stability of filgrastim and epoetin alfa in a system designed for enteral administration in neonates. Ann Pharmacother 2000;34:1257-61. DOI 10.1345/aph.10105
14. Calhoun DA, Chegini N, Polliotti BM, Gersting JA, Miller RK, Christensen RD. Granulocyte colony-stimulating factor in preterm and term pregnancy, parturition, and intra-amniotic infection. Obstet Gynecol 2001;97:229-34.
15. Calhoun DA, Richards BE, Gersting JA, Sullivan SE, Christensen RD. Stability of granulocyte colony-stimulating factor and erythropoietin in human and synthetic amniotic fluid after in vitro simulations of digestion. J Pharm Technol 2002;18:310-5.
16. Hernandez G, Velasco N, Wainstein C, et al. Gut mucosal atrophy after a short enteral fasting period in critically ill patients. J Crit Care 1999;14:73-7.
17. Condino AA, Barleycorn AA, Lu W, Maheshwari A, Christensen RD, Calhoun DA. Abnormal intestinal histology in neonates with congenital anomalies of the gastrointestinal tract. Biol Neonate 2004;85:145-50.
18. Sullivan SE, Calhoun DA, Maheshwari A, et al. Tolerance of simulated amniotic fluid in premature neonates. Ann Pharmacother 2002;36:1518-24. DOI 10.1345/aph.1A439
19. Lima-Rogel V, Calhoun DA, Maheshwari A, et al. Tolerance of a sterile isotonic electrolyte solution containing select recombinant growth factors in neonates recovering from necrotizing enterocolitis. J Perinatol 2003;23:200-4.
20. Lima-Rogel V, Ojeda MA, Villegas C, et al. Tolerance of an enterally administered simulated amniotic fluid-like solution by neonates recovering from surgery for congenital bowel abnormalities. J Perinatol 2004;24:295-8.
21. Christensen RD, Havranek T, Gerstmann DR, Calhoun DA. Enteral administration of a simulated amniotic fluid to very low birth weight neonates. J Perinatol 2005;25:380-5.
22. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90-5.
23. Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004;25:577-83.
24. Olsen NV. Central nervous system frontiers for the use of erythropoietin. Clin Infect Dis 2003;37(suppl 4):S323-30.
25. Juul S. Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol 2004;31:129-42.
26. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998;52:235-49.
27. Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res 1999;46:543-7.
28. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999;126:3597-605.
29. Ledbetter DJ, Juul SE. Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J Pediatr Surg 2000;35:178-82.
30. Juul SE, Ledbetter DJ, Joyce AE, et al. Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 2001;49:182-9.
31. Janjua N, Mayer SA. Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care 2003;9:113-9.
32. Grimm C, Wenzel A, Stanescu D, et al. Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration. J Neurosci 2004;24:5651-8.
33. Gene S, Koroglu TF, Gene K. Erythropoietin as a novel neuroprotectant Restor Neurol Neurosci 2004;22:105-19.
34. Alafaci C, Salpietro F, Grasso G, et al. Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 2000;406:219-25.
35. Buemi M, Cavallaro E, Floccari F, et al. Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin Sci (Lond) 2002;103:275-82.
36. Wang X, Zhu C, Gerwien JG, et al. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 2004;91:900-10.
37. Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983;102:895-906.
38. Betkerur MV, Yeh TF, Miller K, Glasser RJ, Pildes RS. Indomethacin and its effects on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics 1981;68:99-102.
39. Van Bel F, Guit GL, Schipper J, van de Bor M, Baan J. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr 1991;118:621-6.
40. Rennie JM, Doyle J, Cooke RWI. Early administration of indomethacin to preterm infants. Arch Dis Child 1986;61:233-8.
41. Laudignon N, Chemtob S, Bard H, Aranda JV. Effect of indomethacin on cerebral blood flow velocity of premature newborns. Biol Neonate 1988;54:254-62.
42. Coceani F, White E, Bodach E, Olley PM. Age-dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen. Can J Physiol Pharmacol 1979;57:825-31.
43. Chemtob S, Beharry K, Barna T, Varma DR, Aranda JV. Differences in the effects in the newborn piglet of various nonsteroidal antiinflammatory drugs on cerebral blood flow but not on cerebrovascular prostaglandins. Pediatr Res 1991;30:106-11.
44. Chemtob S, Beharry K, Rex J, Varma DR, Aranda JV. Prostenoids determine the range cerebral blood flow autoregulation of newborn piglets. Stroke 1990;21:777-84.
45. Mosca F, Bray M, Colnaghi MR, Fumagalli M, Compagnoni G. Cerebral vasoreactivity to arterial carbon dioxide tension in preterm infants: the effect of ibuprofen. J Pediatr 1999;135:644-6.
46. Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papagerorgiou A, Aranada JV. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA 1996;275:539-44.
47. De Carolis MP, Romagnoli C, Polimeni V, et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr 2000;159:364-8.
48. Dani C, Bertini G, Reali MF, et al. Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. Acta Paediatr 2000;89:1369-74.
49. Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2005;4.
50. Mosca F, Milena B, Stucchi I, Fumagalli M. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 2002;360:1023-4.
51. Gournay V, Savagner C, Thiriez G, Kuster A, Roze J-C. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 2002;359:1486-8.
52. Van Overmeire B, Follens I, Hartmann S, Creten W, Van Acker K. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonate Ed 1997;76:179F-184F.
53. Van Overmeire B, Smets K, Lecoutere D, et al. A comparision of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Eng J Med 2000;343:674-681.
54. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen vs indomethacin in preterm infants treated for patent ductus arteriosus: a randomized controlled trial. Eur J Pediatr 2002;161:202-207.
55. Su PH, Chen JY, Su CM, Huang TC, Lee HS. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatrics International 2003;45:665-670.
56. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards D. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000;47:36-42.
57. Mosca F, Bray M, Lattanzio M, Fumagalli M, Camillo T. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997;131:549-54.
58. Tatli MM, Kumral A, Duman N, Demir K, Gurcu O, Ozkan H. Spontaneous intestinal perforation after oral ibuprofen treatment of patent ducutus arteriosus in two very-low-birth weight infants. Acta Paediatr 2004;93:999-1001.
59. Cooper-Peel C, Brodersen R, Robertson A. Does ibuprofen affect bilirubin-albumin binding in newborn infant serum? Pharmacol Toxicol 1996;79:297-9.
60. Lam BC, Wong HN, Yeung CY. Effect of indomethacin on binding of bilirubin to albumin. Arch Dis Child 1990;65:690-1.
61. Hansen TWR. Ibuprofen for closure of patent ductus arteriosus: is it really safe in hyperbilirubinaemic infants (letter)? Eur J Pediatr 2003;162:356.
62. Lago P. Ibuprofen for closure of patent ductus arteriosus: is it really safe in hyperbilirubinimic infants (letter)? Eur J Pediatr 2003;162:357.
63. Romagnoli C, De Carolis MP, Papacci P, et al. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. Clin Pharmacol Ther 2000;67:676-83.
64. Guy RH, Hadgraft J. Transdermal drug delivery. New York: Marcel Dekker, 1989:59-77.
65. Guy RH, Hadgraft J. Transdermal drug delivery: a perspective. J Control Release 1987;4:237-51.
66. Nayak A, Kalia YN, Guy RH. Transdermal drug delivery; overcoming the skin's barrier function. PSIT 2003;3:318-26.
67. Barker N, Hadgraft J, Rutter N. Skin permeability. J Invest Derm 1987;88:409-11.
68. Kagan BM, Mirman B, Cavlin J, Lundeen E. Cyanosis in premature infants due to aniline dye intoxication. J Pediatr 1949;34:574-8.
69. Curley A, Hawk RE, Kimbrough RD, Natheson G, Finberg L. Dermal absorption of hexachlorophene in infants. Lancet 1971;2:296-7.
70. Harpin V, Rutter N. Percutaneous alcohol absorption and skin necrosis in a preterm infant. Arch Dis Child 1982;57:477-9.
71. Evans NJ, Rutter N, Hadgraft J, Parr G. Percutaneous administration of theophylline in the preterm infant. J Pediatr 1985;107:307-11.
72. Taddio A, Stevens B, Craig K, et al. Efficacy and safety of lidocaine-prilocaine cream for pain during circumcision. N Engl J Med 1997;336:1197-201.
73. Woolfson AD, McCafferty DF. Percutaneous local anaesthesia: drug release characteristics of the amethocaine phase-change system. Int J Pharm 1993;94:75-80.
74. Long CP, McCafferty DF, Sittlington NM, Halliday HL, Woolfson AD, Jones DS. Randomized trial of novel tetracaine patch to provide local anesthesia in neonates undergoing venepuncture. Br J Anaesth 2003;91:514-8.
75. Goldman RD. ELA-max: a new topical lidocaine formulation. Ann Pharmacother 2004;38:892-4. DOI 10.1345/aph.1C423
76. Pelgo O, Bar-Oz B, Arad I. Coma in a premature infant associated with the transdermal absorption of propylene glycol. Acta Paediatr 1998;87:1195-6.
77. Harpin V, Rutter N. Percutaneous alcohol absorption and skin necrosis in a preterm infant. Arch Dis Child 1982;57:477-9.
78. Faura CC, Collins SL, Moore A, McQuay HJ. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 1998;74:43-53.
79. Schultz AA, Strout TD, Jordan P, Worthing B. Safety, tolerability, and efficacy of iontophoresis with lidocaine for dermal anesthesia in ED pediatric patients. J Emerg Nurs 2002;28:289-96.
80. Zhang L, Rabussay DP. Clinical evaluation of safety and human tolerance of electrical sensation induced by electric fields with non-invasive electrodes. Bioelectrochemistry 2002;56:233-6.
81. Katz NP, Shapiro DE, Herrmann TE, Kost J, Custer LM. Rapid onset of cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound-emitting device. Anesth Analg 2004;98:371-6.
82. Matriano JA. Macroflux microprojection array patch technology; a new and efficient approach for intracutaneous immunization. Pharm Res 2002;19:63-70.
83. Finer JJ, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 200;1:CD000399.
84. Macrae DJ, Field D, Mercier JC, et al. Inhaled nitric oxide therapy in neonates and children: reaching a European consensus. Intensive Care Med 2004;30:372-80.
85. Lorts A, Pearl JM, Shanley TP. Bouncing back from inhaled nitric oxide. Pediatr Crit Care Med 2004;5:294-6.
86. Oishi P, Fineman JR. Pharmacologic therapy for persistent pulmonary hypertension of the newborn: as "poly" as the disease itself. Pediatr Crit Care Med 2004;5:94-6.
87. Weinberger B, Heck DE, Laskin DL, Laskin JD. Nitric oxide in the lung: therapeutic and cellular mechanisms of action. Pharmacol Ther 1999;84:401-11.
88. Ivy DD, Kinsella JP, Ziegler JW, Abman SH. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998;115:875-72.
89. Ziegler JW, Ivy DD, Wiggins JW, Kinsella JP, Clarke WR, Abman SH. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med 1998;158:1388-95.
90. Atz AM, Wessel DL. Sildenafil ameliorates effects of nitric oxide withdrawal. Anesthesiology 1999;91:307-10.
91. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomized trial in infants after cardiac surgery. Intensive Care Med 200;29:1996-2003.
92. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers the pulmonary vascular resistance in a model of neonatal meconium aspiration. Am J Respir Crit Care Med 2002;165:1098-102.
93. Altz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM. Sildenafil augments the effect of inhaled nitric oxide for the postoperative pulmonary hypertensive crisis. J Thorac Cardiovasc Surg 2002;124:628-9.
94. Keller RL, Hamrick SEG, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med 2004;5:184-7.
95. Konduri GG, Garcia DC, Kazzi NJ, Shankaran S. Adenosine infusion improves oxygenation in term infants with respiratory failure. Pediatrics 1996;97:295-300.
96. Ng C, Franklin O, Vaidya M, Pierce C, Petros A. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 2004;5:10-3.